Research Article
Is Combination Antiviral Therapy Mandatory for Maintenance Therapy in Fully Suppressed Multidrug-Resistant Hepatitis B Patients?
Table 1
Demographic and baseline characteristics of the patients.
| | Overall () | Combination group () | Single group () | value |
| | Male (%) | 153 (71.2) | 111 (72.5) | 33 (68.8) | 0.74 | | Age, years (IQR) | 53 (48–60) | 54.0 (48–60) | 51 (47–58.3) | 0.44 | | HBeAg-positive (%) | 117 (54.4) | 79 (51.6) | 29 (60.4) | 0.37 | | Previous drug exposure, (%) | | LAM | 182 (84.7) | 131 (85.6) | 39 (81.3) | 0.49 | | LdT | 29 (13.5) | 11 (7.2) | 12 (25.0) | 0.003 | | ETV | 166 (77.2) | 111 (72.5) | 36 (75.0) | 0.85 | | ADV | 156 (72.6) | 121 (79.1) | 34 (70.8) | 0.32 | | HBV-resistant mutations, (%) | | To LAM + LdT | 13 (6.5) | 10 (6.5) | 3 (6.3) | | | To LAM + ETV | 2 (1.0) | 2 (1.3) | 0 (0.0) | | | To LAM + LdT + ETV | 106 (52.7) | 77 (50.3) | 29 (60.4) | | | To LAM + LdT + ADV | 15 (7.5) | 11 (7.2) | 4 (8.3) | | | To LAM + ETV + ADV | 1 (0.5) | 1 (0.7) | 0 (0.0) | | | To LAM + LdT + ETV + ADV | 15 (7.5) | 12 (7.8) | 3 (6.3) | | | To LdT + ADV | 46 (22.9) | 37 (24.2) | 9 (18.8) | | | To ADV only | 3 (1.5) | 3 (2.0) | 0 (0.0) | | | Mutation location, (%) | | rtL180 | 141 (65.6) | 96 (62.7) | 35 (72.9) | 0.23 | | rtA181 | 72 (33.5) | 55 (35.9) | 15 (31.3) | 0.60 | | rtT184 | 65 (30.2) | 42 (27.5) | 20 (41.7) | 0.07 | | rtS202 | 62 (28.8) | 44 (28.8) | 14 (29.2) | 1.00 | | rtM204 | 158 (73.5) | 107 (69.9) | 39 (81.3) | 0.14 | | rtN236 | 24 (11.2) | 17 (11.1) | 7 (14.6) | 0.61 | | rtM250 | 6 (2.8) | 3 (2.0) | 3 (6.3) | 0.15 | | rtA181 and rtN236 | 15 (7.0) | 10 (6.5) | 5 (10.4) | 0.36 | | Underlying LC, (%) | 99 (46.0) | 77 (50.3) | 18 (37.5) | 0.14 | | Previous history of HCC, (%) | 45 (20.9) | 36 (2354) | 6 (12.5) | 0.11 | | Laboratory data, median (IQR) | | AST (IU/L) | 27 (23–34) | 27 (22–35) | 27 (23–34) | 0.37 | | ALT (IU/L) | 26 (21–36) | 26 (21–34) | 26.5 (17.8–37) | 0.21 | | Total bilirubin (mg/dL) | 0.9 (0.7–1.2) | 0.9 (0.7–1.2) | 0.8 (0.6–1.2) | 0.60 | | Albumin (g/dL) | 4.4 (4.2–4.6) | 4.4 (4.2–4.5) | 4.4 (4.3–4.6) | 0.46 | | Creatinine (mg/dL) | 0.9 (0.8–1.0) | 0.9 (0.8–1.0) | 0.9 (0.8–1.0) | 0.31 | | Phosphorous (mg/dL) | 3.3 (3.0–3.6) | 3.3 (2.9–3.6) | 3.3 (3.1–3.5) | 0.78 |
|
|
Data are (%) or median (IQR). ADV: adefovir; ALT: alanine aminotransferase; AST: aspartate aminotransferase; ETV: entecavir; HBV: hepatitis B virus; HCC: hepatocellular carcinoma; IQR: interquartile range; LAM: lamivudine; LC: liver cirrhosis; LdT: telbivudine; SD: standard deviation. |
